6,7-Dimethoxy-4-(6-quinolyloxy)quinoline

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6,7-Dimethoxy-4-(6-quinolyloxy)quinoline
• 英文别名: 6,7-dimethoxy-4-quinolin-6-yloxyquinoline
• 化学式: C₂₀H₁₆N₂O₃
• 分子量: 332.359
• InChiKey: BBOWAINCQIWQGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  53.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-羟基喹啉 、 4-氯 -6,7-二甲氧基喹啉 在 silica gel 作用下， 反应 0.5h， 以to give the title compound (62 mg, yield 46%)的产率得到6,7-Dimethoxy-4-(6-quinolyloxy)quinoline
  参考文献：
  名称：

  COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

  摘要：

  本发明提供了由式(I)表示的化合物及其药学上可接受的盐和溶剂： 其中，X代表CH或N；Z代表—O—、—NH—或—C(═O)—；R和R′代表氢原子、羟基、卤素原子、可选取代的烷基、可选取代的烯基、可选取代的烷氧基、氨基、氨基甲酰基或可选取代的杂环基；A代表可选取代的特定环烷基或杂环基。本发明的化合物具有优异的TGFβ抑制活性。

  公开号：

  US20090312313A1

文献信息

• Quinoline and quinazoline derivatives inhibiting platelet-derived growth
  申请人：Kirin Beer Kabushiki Kaisha

  公开号：US06143764A1

  公开（公告）日：2000-11-07

  The present invention relates to novel quinoline derivatives and quinazoline derivatives represented by the following formula (I): ##STR1## [wherein R.sub.1 and R.sub.2 are each independently H or C.sub.1 -C.sub.4 -alkyl, or R.sub.1 and R.sub.2 together form C.sub.1 -C.sub.3 -alkylene, X is O, S or CH.sub.2, W is CH or N, and Q is a substituted aryl group or substituted heteroaryl group] and their pharmaceutically acceptable salts, having platelet-derived growth factor receptor autophosphorylation inhibitory activity, to pharmaceutical compositions containing these compounds, and to methods for the treatment of diseases associated with abnormal cell growth such as tumors.

  本发明涉及由以下式（I）表示的新型喹啉衍生物和喹唑啉衍生物：[其中R.sub.1和R.sub.2分别独立地为H或C.sub.1 -C.sub.4 -烷基，或R.sub.1和R.sub.2一起形成C.sub.1 -C.sub.3 -烷基，X为O、S或CH.sub.2，W为CH或N，Q为取代芳基或取代杂芳基]及其在药学上可接受的盐，具有血小板源性生长因子受体自磷酸化抑制活性，用于含有这些化合物的药物组合物，以及用于治疗与异常细胞生长（如肿瘤）相关的疾病的方法。
• Compound having tgfß inhibitory activity and medicinal composition containing the same
  申请人：Shimizu Kiyoshi

  公开号：US20060111375A1

  公开（公告）日：2006-05-25

  The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents —O—, —NH— or —C(═O)—; R and R′ represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGFβ inhibitory activity.

  本发明提供了以下公式（I）所表示的化合物及其药学上可接受的盐和溶剂： 其中，X代表CH或N；Z代表-O-，-NH-或-C（=O）-；R和R'代表氢原子，羟基，卤原子，可选择取代的烷基，可选择取代的烯基，可选择取代的烷氧基，氨基，氨基甲酰基或可选择取代的杂环基；A代表可选择取代的特定环烷基或杂环基。本发明的化合物具有出色的TGFβ抑制活性。
• COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：Shimizu Kiyoshi

  公开号：US20090312313A1

  公开（公告）日：2009-12-17

  The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents —O—, —NH— or —C(═O)—; R and R′ represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGFβ inhibitory activity.

  本发明提供了由式(I)表示的化合物及其药学上可接受的盐和溶剂： 其中，X代表CH或N；Z代表—O—、—NH—或—C(═O)—；R和R′代表氢原子、羟基、卤素原子、可选取代的烷基、可选取代的烯基、可选取代的烷氧基、氨基、氨基甲酰基或可选取代的杂环基；A代表可选取代的特定环烷基或杂环基。本发明的化合物具有优异的TGFβ抑制活性。
• COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
  申请人：KIRIN BEER KABUSHIKI KAISHA

  公开号：EP1548008A1

  公开（公告）日：2005-06-29

  The present invention provides compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein X represents CH or N; Z represents -O-, -NH- or - C(=O)-; R and R' represent a hydrogen atom, hydroxyl, a halogen atom, optionally substituted alkyl, optionally substituted alkenyl optionally substituted alkoxy, amino, aminocarbonyl, or an optionally substituted heterocyclic group; and A represents an optionally substituted specific carbocyclic or heterocyclic group. The compounds according to the present invention have excellent TGFβ inhibitory activity.

  本发明提供了式 (I) 所代表的化合物及其药学上可接受的盐和溶剂： 其中 X 代表 CH 或 N；Z 代表 -O-、-NH- 或 -C(=O)-；R 和 R' 代表氢原子、羟基、卤素原子、任选取代的烷基、任选取代的烯基、任选取代的烷氧基、氨基、氨基羰基或任选取代的杂环基团；A 代表任选取代的特定碳环或杂环基团。本发明的化合物具有优异的 TGFβ 抑制活性。
• EP1548008
  申请人：——

  公开号：——

  公开（公告）日：——